Robert Azelby

Robert W.
Azelby is currently Chairman at Tango Therapeutics, Inc. since 2026.
He is an Independent Non-Executive Director at ADC Therapeutics SA since 2023.
He serves as Non-Executive Director at Autolus Therapeutics Plc and Independent Director at Cardinal Health, Inc., both since 2024.
Formerly, Mr. Azelby was Chief Executive Officer at Masimo Corp.
from 2024 to 2025.
He was President, Chief Executive Officer & Director at Climb Bio, Inc. from 2020 to 2023 and at Lundbeck Seattle BioPharmaceuticals, Inc. from 2018 to 2019.
He was Independent Director at Clovis Oncology, Inc. from 2018 to 2023 and Independent Director at Terns Pharmaceuticals, Inc. from 2025 to 2026.
He held the role of Chief Commercial Officer & Executive VP at Juno Therapeutics, Inc. from 2015 to 2018.
He was Vice President & General Manager-Oncology at Amgen, Inc. from 2012 to 2015 and VP-Commercial Effectiveness Unit & General Manager at Amgen Europe BV.
He was Director at Immunomedics, Inc. in 2020, at Cascadian Therapeutics LLC from 2017 to 2018, and at the Alliance for Regenerative Medicine.
He was Independent Director at Chinook Therapeutics, Inc. in 2023.
Education includes an undergraduate degree from the University of Virginia and an MBA from Harvard Business School conferred in 1997.